Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Immunovant, Inc. logo
Immunovant, Inc.IMVT
——
Natera, Inc. logo
Natera, Inc.NTRA
——
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Bicara Therapeutics (BCAX) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $11.87M in Q1 2026.
How has Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 43.6% year-over-year, from $8.27M to $11.87M.
What is the long-term trend for Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number?
Over 2 years (2023 to 2025), Bicara Therapeutics's share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 42.5% compound annual growth rate (CAGR), from $4.85M to $9.85M.